Invigo Therapeutics

Active

Private limited companyfounded 2022active for 4 yearsNonnenstraat 23, 2800 Mechelen, BelgiumKBO/BCE: BE 0789.481.317

Summary

Invigo Therapeutics has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €2,055 and a net result of €9,011. Equity is shrinking by about 55% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2027. The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow Report Compare

Invigo TherapeuticsActiveChecked score 97/100

Risk analysis Report Compare

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

NACE 21209

1 site

Size

€2,055total assets 2026

Equity: €2,055
Profit: €9,011

Turnover not published (micro format)

Financial health

97 Excellent Checked score 2026

Bankruptcy probabilitywithin 12 months: 0.1%

Structure

2026 accounts 33 days early1 deed in the Belgian Official Gazette

Why 97raises riskSize: total assets €2,055lowers riskLiquidity: cash €2,053Sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)Equity €2,055 (100.0% of total assets)Show the evidence

Checked score

Score 2026

97 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 93% of its sector peers (NACE 21, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2025

Strong

Solvency 100+100

equity 100.0% of total assets

Liquidity 100+50

short-term debt 0.0% · cash 99.9%

Profitability 100+100

return on assets 438.4%

Bankruptcy probability, 12 months

0.1% Very low

0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (154 companies, NACE 21, micro)

Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.4%▲ +0.1 percentage points vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.6%▲ +0.2 percentage points vs 10-2025 12-2025: 0.9%▲ +0.3 percentage points vs 11-2025highest value 01-2026: 0.9%● unchanged vs 12-2025highest value 02-2026: 0.9%● unchanged vs 01-2026highest value 03-2026: 0.9%● unchanged vs 02-2026highest value 04-2026: 0.7%▼ -0.2 percentage points vs 03-2026 05-2026: 0.7%● unchanged vs 04-2026 06-2026: 0.7%● unchanged vs 05-2026 07-2026: 0.6%▼ -0.1 percentage points vs 06-2026 08-2026: 0.7%▲ +0.1 percentage points vs 07-2026 09-2026: 0.7%● unchanged vs 08-2026 10-2026: 0.1%▼ -0.6 percentage points vs 09-2026lowest value

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 90% on solvency, 96% on liquidity, 94% on profitability and 93% on growth.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: cash €2,053

NBB · annual accounts

Size: total assets €2,055

Companies of this size fail more often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)

KBO

Equity €2,055 (100.0% of total assets)

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 28-09-2026, 33 days ahead of the deadline.

NBB · 3 filings

Deviation from the deadline

2026

33 days early

2025

on the day

2024

31 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 21 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 30 September (3 of the last 3 filed years within 31 days of that day).

Companies Code · seven months

Where today falls in the filing period

26-10-2026 today31-03-2027 year end31-10-2027 deadline

No strike-offs in the KBO publications

Searched since incorporation in 2022.

KBO publications · our coverage

28-09-2026 Annual accounts filedfinancial year 2026 · micro…
31-03-2026 Back to profitnet €9,011
31-10-2025 Annual accounts filedfinancial year 2025 · micro…

Key points

Total assets 20263 financial years filed €2,055 View
Active since 2022founded 08-08-2022 4 years View

By topic

Financials

Financial year: 2026
Total assets: €2,055
Profit: €9,011
Solvency: 100.0%

Total assets▲ 117%

Net result

20242026

Go to Financials

Timeline

Events: 5
Since: 2024
Next accounts: by 31-10-2027

31-03-2025Weakest financial year
30-09-2024Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
Founded: 08-08-2022
Year ends: 31-03
Peppol: Reachable for e-invoices

Go to Company details

Key facts about Invigo Therapeutics

What is the company number of Invigo Therapeutics?: 0789.481.317. In Belgium the VAT number is the company number with BE in front: BE 0789.481.317.
Where is Invigo Therapeutics based?: The registered office is at Nonnenstraat 23, 2800 Mechelen.Company details
What does Invigo Therapeutics do?: According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21209).
What is the legal form of Invigo Therapeutics?: Private limited company (BV).
When was Invigo Therapeutics founded?: On 08-08-2022.
Is Invigo Therapeutics still active?: Yes, Invigo Therapeutics is an active enterprise in the KBO register.
What is the turnover of Invigo Therapeutics?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is Invigo Therapeutics profitable?: In financial year 2026, Invigo Therapeutics made a profit of €9,011.
Where can I find the annual accounts of Invigo Therapeutics?: Invigo Therapeutics filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of Invigo Therapeutics due?: By 31-10-2027, for financial year 2027.Timeline